KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) — insider trading
Health Care · NASDAQ
KINIKSA PHARMACEUTICALS INTERNATIO (KNSA) has 43 reported SEC Form 4 insider transactions in our data, including 3 open-market sales among the most recent 43 (latest 2026-07-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-01 | Malkani Dhiraj H | Officer (CHIEF STRATEGY OFFICER) | Grant / award / vesting (derivative) | 1,307 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Malkani Dhiraj H | Officer (CHIEF STRATEGY OFFICER) | Grant / award / vesting (derivative) | 1,245 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Malkani Dhiraj H | Officer (CHIEF STRATEGY OFFICER) | Grant / award / vesting (derivative) | 2,188 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Malkani Dhiraj H | Officer (CHIEF STRATEGY OFFICER) | Grant / award / vesting (derivative) | 2,119 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Malkani Dhiraj H | Officer (CHIEF STRATEGY OFFICER) | Grant / award / vesting (derivative) | 14,000 | $0.00 | $0 | Form 4 |
| 2026-07-01 | Malkani Dhiraj H | Officer (CHIEF STRATEGY OFFICER) | Grant / award / vesting (derivative) | 82,600 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Patel Sanj K | Director, Officer (CHAIRMAN & CEO) | Conversion of derivative (derivative) | 900,000 | $0.00 | $0 | Form 4 |
| 2026-06-01 | Patel Sanj K | Director, Officer (CHAIRMAN & CEO) | Conversion of derivative | 900,000 | — | — | Form 4 |
| 2026-05-29 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director | Grant / award / vesting (derivative) | 36,474 | $0.00 | $0 | Form 4 |
| 2026-05-29 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director | Grant / award / vesting (derivative) | 36,474 | $0.00 | $0 | Form 4 |
| 2026-05-29 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director | Grant / award / vesting | 6,078 | $0.00 | $0 | Form 4 |
| 2026-05-29 | BAKER BROS. ADVISORS LP; 667, L.P.; Baker Bros. Advisors (GP) LLC; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN | Director | Grant / award / vesting | 6,078 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Cole G Bradley | Director | Option exercise / conversion (derivative) | 2,799 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Cole G Bradley | Director | Grant / award / vesting (derivative) | 2,026 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Cole G Bradley | Director | Grant / award / vesting (derivative) | 12,158 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Cole G Bradley | Director | Option exercise / conversion | 2,799 | — | — | Form 4 |
| 2026-05-29 | Levy Richard S | Director | Option exercise / conversion (derivative) | 2,799 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Levy Richard S | Director | Grant / award / vesting (derivative) | 2,026 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Levy Richard S | Director | Grant / award / vesting (derivative) | 12,158 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Levy Richard S | Director | Option exercise / conversion | 2,799 | — | — | Form 4 |
| 2026-05-29 | Malley Thomas | Director | Option exercise / conversion (derivative) | 2,799 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Malley Thomas | Director | Grant / award / vesting (derivative) | 2,026 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Malley Thomas | Director | Grant / award / vesting (derivative) | 12,158 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Malley Thomas | Director | Option exercise / conversion | 2,799 | — | — | Form 4 |
| 2026-05-29 | McCain Tracey L | Director | Option exercise / conversion (derivative) | 2,799 | $0.00 | $0 | Form 4 |
| 2026-05-29 | McCain Tracey L | Director | Grant / award / vesting (derivative) | 2,026 | $0.00 | $0 | Form 4 |
| 2026-05-29 | McCain Tracey L | Director | Grant / award / vesting (derivative) | 12,158 | $0.00 | $0 | Form 4 |
| 2026-05-29 | McCain Tracey L | Director | Option exercise / conversion | 2,799 | — | — | Form 4 |
| 2026-05-29 | Popovits Kimberly J | Director | Option exercise / conversion (derivative) | 2,799 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Popovits Kimberly J | Director | Grant / award / vesting (derivative) | 2,026 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Popovits Kimberly J | Director | Grant / award / vesting (derivative) | 12,158 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Popovits Kimberly J | Director | Option exercise / conversion | 2,799 | — | — | Form 4 |
| 2026-05-29 | Quart Barry D | Director | Option exercise / conversion (derivative) | 2,799 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Quart Barry D | Director | Grant / award / vesting (derivative) | 2,026 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Quart Barry D | Director | Grant / award / vesting (derivative) | 12,158 | $0.00 | $0 | Form 4 |
| 2026-05-29 | Quart Barry D | Director | Option exercise / conversion | 2,799 | — | — | Form 4 |
| 2026-05-01 | Paolini John F. | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion (derivative) | 58,424 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Paolini John F. | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 21,097 | $54.04 | $1.14M | Form 4 |
| 2026-05-01 | Paolini John F. | Officer (CHIEF MEDICAL OFFICER) | Open-market sale | 37,327 | $53.52 | $2.00M | Form 4 |
| 2026-05-01 | Paolini John F. | Officer (CHIEF MEDICAL OFFICER) | Option exercise / conversion | 58,424 | $10.36 | $605.3K | Form 4 |
| 2026-05-01 | Patel Sanj K | Director, Officer (CHAIRMAN & CEO) | Option exercise / conversion (derivative) | 48,565 | $0.00 | $0 | Form 4 |
| 2026-05-01 | Patel Sanj K | Director, Officer (CHAIRMAN & CEO) | Open-market sale | 48,565 | $54.02 | $2.62M | Form 4 |
| 2026-05-01 | Patel Sanj K | Director, Officer (CHAIRMAN & CEO) | Option exercise / conversion | 48,565 | $30.93 | $1.50M | Form 4 |
Ask the chat about KNSA's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: KINIKSA PHARMACEUTICALS INTERNATIO (KNSA).
Last updated 2026-07-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.